Operator
Hello, everyone, and thank you for joining the ANGLE 2025 Interim Results Call. My name is Claire, and I will be coordinating your call today. [Operator Instructions]
I will now hand over to Andrew Newland, CEO. Please begin.
Andrew David Newland
Founder, CEO & Executive Director
Good morning, everybody, and welcome to ANGLE’s interims webcast for 2025. It’s been a very strong half year in terms of major progress in commercialization on multiple fronts. However, there has been strong revenue pressure from adverse market conditions. So it’s a balanced 6-month period.
As you know, ANGLE has developed a breakthrough product for cancer diagnostics, which can be used to help patients get better outcomes by making sure that they have more appropriate treatment and also reduce health care costs. We’re getting closer to its deployment widely for patients. We’ve had 3 major achievements during the half year, which are in relation to large pharma contracts, DNA dual analysis and cluster buster drugs. So I will tell you about those now.
First and very importantly, our large pharma strategy, which we’ve developed as a way of accessing development funds to progress clinical trials in support of Parsortix has progressed well. The idea here is that pharma can fund for their own drug development purposes, individual clinical trials and that they can actually lead eventually to a companion diagnostic based on the Parsortix system and wide adoption. So as you know, we’ve had 3 pharma projects — large pharma projects that we’ve
#ANGLE #Plc #ADR #ANPCY #Earnings #Call #Transcript